In addition to CIs, molecular-targeted therapies against the most common NSCLC drivers (the mutated epidermal growth factor receptor, EGFR, and the translocated anaplastic lymphoma kinase, ALK) have been developed and clinically approved [21,22,23,24]. This evidence concerns the gene ALK and non-small cell lung carcinoma.